SIG
GBT

Stanford Investment Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Stanford Investment Group’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,400
Closed -$20K – 324
2016
Q4 		$20K Hold
1,400
– – 0.01% 254
2016
Q3 		$32K Hold
1,400
– – 0.02% 203
2016
Q2 		$23K Hold
1,400
– – 0.01% 236
2016
Q1 		$22K Buy
+1,400
New +$24.9K 0.01% 235

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WSC
White Square Capital London, United Kingdom $14.7M AUM 151.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Stanford Investment Group's GBT Position: Q1 2017 in Review

Stanford Investment Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2017, closing a stake of 1,400 shares — an estimated $20K sold.

Stanford Investment Group first reported a position in GBT in Q1 2016 and held it in 4 quarters. The position peaked at $32K in Q3 2016. 116 funds tracked by Wall St. Rank hold GBT as of Q1 2017.

  • Stanford Investment Group reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 1,400 Global Blood Therapeutics, Inc. shares in Q1 2017, an estimated $20K.
  • Stanford Investment Group first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Stanford Investment Group's Global Blood Therapeutics, Inc. position peaked at $32K in Q3 2016.
  • 116 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.